Terazosin for Dementia With Lewy Bodies
ConditionDementia With Lewy Bodies
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age0-90
SponsorQiang Zhang
About this trial
The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.
Eligibility criteria
Qualifiers
Men or women with the diagnosis of dementia with Lewy Bodies per 2017 DLB Consortium criteria.
Baseline MOCA 18 or above. On stable AChEI and/or memantine treatment regimen for ≥4 weeks prior to baseline.
Disqualifiers
Subjects unwilling or unable to give informed consent
No confounding acute or unstable medical, psychiatric, orthopedic condition. Subjects who have hypertension, diabetes mellitus, depression, or other common age-related illness will be included if their disease under control with stable treatment regimen for at least 30 days.
Orthostatic hypotension defined as symptomatic decrease in BP > 20mmHg systolic or > 10mmHg diastolic on supine to sitting or standing, or a sitting blood pressure of ≤90/60.
Clinically significant traumatic brain injury or post-traumatic stress disorder
Trial design
Treatments tested in this trial
- Terazosin Hydrochloride
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Qiang Zhang
Lead sponsor
University of Iowa
Sponsor institution
Source ClinicalTrials.gov